Author:
Bey P.,Wilkinson P. M.,Resbeut M.,Bourdin S.,Le Floch O.,Hahne W.,Claverie N.
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Andrews PLR, Howthorn J, Sanger GJ (1986) The effect of abdominal visceral nerve lesions and a novel 5-HT-M receptor antagonist on cytotoxic and radiation-induced emesis in the ferret. J Physiol 382:47P
2. Audhuy B, Cappelaeare P, Claverie N (1995) Double-blind comparative trial of the antiemetic efficacy of two i.v. doses of dolasetron mesilate (DM) and granisetron (G) after infusion with high-dose cisplatin chemotherapy (abstract). Eur J Cancer 31A [Suppl 5]:S253
3. Bigaud M, Elands J, Kastner PR, Bohnke RA, Emmert LW, Galvan M (1995) Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dev Res 34:289–296
4. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Clavel M, Giovannini M, Khayat D, Claverie N, Hahne W (1995) IV Dolasetron (DM) vs IV metoclopramide (M) in emesis prevention after cisplatin chemotherapy (CT) (abstract). Support Care Cancer 3:336
5. Conroy T, Cappelaere P, Fabbro M, et al (1994) Acute antiemetic efficacy and safety of dolasetron mesilate, a 5HT3 antagonist, in cancer patients treated with cisplatin. J Clin Oncol 17:97–102
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献